Severe Alcohol‐Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure

Kavish R. Patidar, Jennifer L. Peng, Harleen Kaur, Astin Worden, Carla D. Kettler, Francis Pike, Caitriona A. Buckley, Eric S. Orman, Archita P Desai, Lauren D. Nephew, Chandrashekhar A. Kubal, Samer Gawrieh, Naga Chalasani, Marwan S. Ghabril – 2 December 2021 – Differences in mortality between critically ill patients with severe alcohol‐associated hepatitis (sAH) and acute‐on‐chronic liver failure (ACLF) and non‐sAH ACLF (i.e., ACLF not precipitated by sAH) are unknown. Such differences are important, as they may inform on prognosis and optimal timing of liver transplantation (LT).

Practices and Perceptions of Living Donor Liver Transplantation, Nondirected Donation, and Liver Paired Exchange: A National Survey

Alyson Kaplan, Russell Rosenblatt, Whitney Jackson, Benjamin Samstein, Robert S. Brown – 2 December 2021 – Living donor liver transplantation (LDLT) remains underutilized in the United States. Barriers to LDLT and acceptance of nondirected living liver donation (ND‐LLD) and liver paired exchange (LPE) are unclear. The medical and surgical directors of 99 unique transplantation programs (56 LDLT programs and 43 non‐LDLT programs) were surveyed to gain insight into perceptions and practices of LDLT and types of donors utilized. The response rate was 84%.

Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?

Gonzalo Sapisochin, Tommy Ivanics, Julie Heimbach – 2 December 2021 – Cholangiocarcinoma (CCA) represents the second‐most common primary liver malignancy after HCC and has risen in incidence globally in the past decades. Intrahepatic cholangiocarcinoma (iCCA) comprises 20% of all CCAs, with the rest being extrahepatic (including perihilar [pCCA] and distal CCA). Though long representing an absolute contraindication for liver transplantation (LT), recent analyses of outcomes of LT for iCCA have suggested that iCCA may be a potentially feasible option for highly selected patients.

A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis

Cihan Yurdaydin, Onur Keskin, Esra Yurdcu, Aysun Çalişkan, Soner Önem, Fatih Karakaya, Çağdaş Kalkan, Ersin Karatayli, Senem Karatayli, Ingrid Choong, David Apelian, Christopher Koh, Theo Heller, Ramazan Idilman, A. Mithat Bozdayi, Jeffrey S. Glenn – 2 December 2021

Sphingosine‐1‐phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy

Hironari Kawai, Yosuke Osawa, Michitaka Matsuda, Tomoyuki Tsunoda, Keisuke Yanagida, Daisuke Hishikawa, Miku Okawara, Yuzuru Sakamoto, Tomonari Shimagaki, Yuriko Tsutsui, Yuichi Yoshida, Shiori Yoshikawa, Kana Hashi, Hiroyoshi Doi, Taizo Mori, Taiji Yamazoe, Sachiyo Yoshio, Masaya Sugiyama, Daisuke Okuzaki, Haruki Komatsu, Ayano Inui, Miwa Tamura‐Nakano, Chinatsu Oyama, Hideo Shindou, Hironori Kusano, Masayoshi Kage, Toru Ikegami, Katsuhiko Yanaga, Tatsuya Kanto – 1 December 2021

Subscribe to